Ann: PainChek receives FDA regulatory guidance, page-84

yes i know both techs well... i got stopped out of RAP along long time ago from an investment standpoint around brexit time. The risk always outweighed the reward plus 25c, to re- invest.

Then the obvious occured around the trials. So yes i am very familiar with the tech. but i don't see any benefits of drawing comparisons for either tech with one another other than the sake of drawing comparisons. Both great techs, both seem to have great management / R&D. But there are many more differences and one has zero baring on the other.

Looks like a healthy support level around 6c has stabilised after Mr markets impatience from the FDA ann. 6c was always support below the 6.5 which broke.

so 6.5 resistance to break through after this consolidation period.

yes i topped up at these levels.